home / stock / alim / alim articles

ALIM Articles, Alimera Sciences Inc. - From 07/08/24

Stock Information
Company Name: Alimera Sciences Inc.
Stock Symbol: ALIM
Market: NASDAQ
Website: alimerasciences.com
Menu
ALIM ALIM Quote ALIM Short ALIM News ALIM Articles ALIM Message Board
Get ALIM Alerts

News, Short Squeeze, Breakout and More Instantly...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, MORF, AGR on Behalf of Shareholders | Benzinga

NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potentia...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, SRDX, ATRI on Behalf of Shareholders | Benzinga

NEW YORK, July 04, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potentia...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRFT, SBOW, ALIM, HCP on Behalf of Shareholders | Benzinga

NEW YORK, July 02, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potentia...

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, SBOW, AGR, RPHM on Behalf of Shareholders | Benzinga

NEW YORK, June 25, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potentia...
Nasdaq Records Worst Session Since April With Nvidia Plunging 7%: Dow Jones Sees Modest Gains Amid Mixed Market Close | Benzinga

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the “Fear” zone...

Dow Jumps 300 Points; Alimera Sciences Shares Spike Higher | Benzinga

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.80% to 39,463...

Generics Player ANI Pharmaceuticals Strengthens Rare Disease Segment With $380M Alimera Sciences Deal | Benzinga

On Monday, ANI Pharmaceuticals Inc (NASDAQ:ANIP) agreed to acquire Alimera Sciences Inc (NASDAQ:ALIM) for $5.50 per share in cash and one non-trada...
ALIM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Alimera Sciences to ANI Pharmaceuticals | Benzinga

MONSEY, N.Y., June 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Al...

ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences | Benzinga

Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approxim...

Alimera Sciences Reports Q1 Loss, Misses Revenue Estimates | Benzinga

Alimera Sciences (NASDAQ: ALIM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This comp...
Previous 10 Next 10